These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 33905348)
1. Cysteinylated Albumin as a Potential Biomarker for the Progression of Kidney Disease in Patients With Type 2 Diabetes. Imafuku T; Watanabe H; Oniki K; Yoshida A; Kato H; Nakano T; Tokumaru K; Fujita I; Arimura N; Maeda H; Sakamoto Y; Kondo N; Morita A; Saruwatari J; Tanaka M; Matsushita K; Wada T; Fukagawa M; Otagiri M; Fitzgerald ML; Jinnouchi H; Maruyama T Diabetes Care; 2021 Jun; 44(6):e115-e117. PubMed ID: 33905348 [No Abstract] [Full Text] [Related]
2. Plasma osteoprotegerin as a biomarker of poor glycaemic control that predicts progression of albuminuria in type 2 diabetes mellitus: A 3-year longitudinal cohort study. Moh AMC; Pek SLT; Liu J; Wang J; Subramaniam T; Ang K; Sum CF; Kwan PY; Lee SBM; Tang WE; Lim SC Diabetes Res Clin Pract; 2020 Mar; 161():107992. PubMed ID: 32032675 [TBL] [Abstract][Full Text] [Related]
3. Plasma Leucine-Rich α-2-Glycoprotein 1 Predicts Rapid eGFR Decline and Albuminuria Progression in Type 2 Diabetes Mellitus. Liu JJ; Pek SLT; Ang K; Tavintharan S; Lim SC; J Clin Endocrinol Metab; 2017 Oct; 102(10):3683-3691. PubMed ID: 28973352 [TBL] [Abstract][Full Text] [Related]
4. Profibrotic Circulating Proteins and Risk of Early Progressive Renal Decline in Patients With Type 2 Diabetes With and Without Albuminuria. Ihara K; Skupien J; Kobayashi H; Md Dom ZI; Wilson JM; O'Neil K; Badger HS; Bowsman LM; Satake E; Breyer MD; Duffin KL; Krolewski AS Diabetes Care; 2020 Nov; 43(11):2760-2767. PubMed ID: 32887710 [TBL] [Abstract][Full Text] [Related]
6. Systolic blood pressure as a predictor of incident albuminuria and rapid renal function decline in type 2 diabetic patients. Sheen YJ; Lin JL; Li TC; Bau CT; Sheu WH J Diabetes Complications; 2014; 28(6):779-84. PubMed ID: 25219331 [TBL] [Abstract][Full Text] [Related]
7. Novel biomarkers of diabetic kidney disease: current status and potential clinical application. Barutta F; Bellini S; Canepa S; Durazzo M; Gruden G Acta Diabetol; 2021 Jul; 58(7):819-830. PubMed ID: 33528734 [TBL] [Abstract][Full Text] [Related]
9. Clinical update: The important role of dual kidney function testing (ACR and eGFR) in primary care: Identification of risk and management in type 2 diabetes. Seidu S; Barrat J; Khunti K Prim Care Diabetes; 2020 Aug; 14(4):370-375. PubMed ID: 32139245 [TBL] [Abstract][Full Text] [Related]
11. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100 [TBL] [Abstract][Full Text] [Related]
12. Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Elajami TK; Alfaddagh A; Lakshminarayan D; Soliman M; Chandnani M; Welty FK J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28710178 [TBL] [Abstract][Full Text] [Related]
13. Identification of biomarkers for early diagnosis of diabetic nephropathy disease using direct flow through mass spectrometry. Nilavan E; Sundar S; Shenbagamoorthy M; Narayanan H; Nandagopal B; Srinivasan R Diabetes Metab Syndr; 2020; 14(6):2073-2078. PubMed ID: 33125920 [TBL] [Abstract][Full Text] [Related]
14. Urinary heme oxygenase-1 as a potential biomarker for early diabetic nephropathy. Li Z; Xu Y; Liu X; Nie Y; Zhao Z Nephrology (Carlton); 2017 Jan; 22(1):58-64. PubMed ID: 26733347 [TBL] [Abstract][Full Text] [Related]
15. Heart rate-corrected QT interval is a novel risk marker for the progression of albuminuria in people with Type 2 diabetes. Hashimoto Y; Tanaka M; Senmaru T; Okada H; Hamaguchi M; Asano M; Yamazaki M; Oda Y; Hasegawa G; Nakamura N; Fukui M Diabet Med; 2015 Sep; 32(9):1221-6. PubMed ID: 25683576 [TBL] [Abstract][Full Text] [Related]
16. A difference in systolic blood pressure between arms is a novel predictor of the development and progression of diabetic nephropathy in patients with type 2 diabetes. Okada H; Fukui M; Tanaka M; Matsumoto S; Iwase H; Kobayashi K; Asano M; Yamazaki M; Hasegawa G; Nakamura N Atherosclerosis; 2013 Oct; 230(2):198-201. PubMed ID: 24075744 [TBL] [Abstract][Full Text] [Related]
17. ALCAM a novel biomarker in patients with type 2 diabetes mellitus complicated with diabetic nephropathy. Sulaj A; Kopf S; Gröne E; Gröne HJ; Hoffmann S; Schleicher E; Häring HU; Schwenger V; Herzig S; Fleming T; Nawroth PP; von Bauer R J Diabetes Complications; 2017 Jun; 31(6):1058-1065. PubMed ID: 28325697 [TBL] [Abstract][Full Text] [Related]
18. [Dangerous deficits in management of hypertensive diabetic patients. A kidney check is far from standard procedure]. MMW Fortschr Med; 2003 Apr; 145(17):55. PubMed ID: 12808810 [No Abstract] [Full Text] [Related]
19. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. Dalla Vestra M; Mussap M; Gallina P; Bruseghin M; Cernigoi AM; Saller A; Plebani M; Fioretto P J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S78-82. PubMed ID: 15938041 [TBL] [Abstract][Full Text] [Related]
20. Diabetic kidney disease and vascular comorbidities in patients with type 2 diabetes mellitus in a developing country. Bentata Y; Chemlal A; Karimi I; El Alaoui F; Haddiya I; Abouqal R Saudi J Kidney Dis Transpl; 2015 Sep; 26(5):1035-43. PubMed ID: 26354588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]